Journal of Diabetes and Its Complications
Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study
Trial in 182 peopleInterventions
6 months, cohort study, multicentre, declared ties to: Tanabe Pharma, Daiichi Sankyo, Novo Nordisk Pharma and 10 more
- Tirzepatide
- GLP-1 and incretin signalling
- Lipid and ceramide metabolism
- Type 2 diabetes
- Metabolic dysfunction-associated steatotic liver disease
- Humans
The paper
Asahikawa Medical University
Journal of Diabetes and Its Complications, 14 Aug 2026
